Promises and challenges of cardiac organoids

Li, Jingxian; Yang, Jingsi; Zhao, Dandan; Lei, Wei; Hu, Shijun

doi:10.1007/s00335-023-09987-y

Cited by 3 publications

(4 citation statements)

References 43 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…A patient-specific hiPSC-CM was used to generalize the SQTS disease phenotype at the cellular and tissue levels. Subsequently, mutations in the KCNH9 gene in cardiac organoid cells of SQTS patients were corrected using CRISPR/Cas2 gene editing technology, which could produce normal cardiac organoids [ 158 , 159 ]. The results demonstrate the potential of CRISPR/Cas technology in organoid research.…”

Section: Cardiovascular Organoid Construction Schemementioning

confidence: 99%

“…Cardiogenesis is a complex process that requires intercellular signaling or interactions between tissues to ensure the normal progression of the developmental process. The emergence of cardiac organoids also provides a way to explore key drivers of the heart's development to maturity [ 158 ]. By reflecting the early stages of cardiac development, cardiac organoids provide a new way to study the mechanisms of heart malformations associated with early embryogenesis.…”

Section: Application Of Cardiovascular Organoidsmentioning

confidence: 99%

“…One study has used tissue engineering to embed human pluripotent stem cell aggregates in the matrix gel and then conducted directional cardiac differentiation through small-molecule biphasic WNT pathway regulation to generate highly structured three-dimensional heart-forming organoids for the study of early cardiac development patterns [ 172 ]. The establishment of cardiac organoids provides a method for studying the different developmental stages of the heart [ 158 ]. One study describes a self-organizing human multilineage organoid that reproduces the co-emergence of the anterior epicardium, septal transverse mesenchyme, and liver buds [ 173 ].…”

Section: Application Of Cardiovascular Organoidsmentioning

confidence: 99%

See 2 more Smart Citations

Progress of organoid platform in cardiovascular research

Du,

Jia,

Chang

et al. 2024

Bioactive Materials

View full text Add to dashboard Cite

Section: Cardiovascular Organoid Construction Schemementioning

confidence: 99%

Section: Application Of Cardiovascular Organoidsmentioning

confidence: 99%

Section: Application Of Cardiovascular Organoidsmentioning

confidence: 99%

See 1 more Smart Citation

Progress of organoid platform in cardiovascular research

Du,

Jia,

Chang

et al. 2024

Bioactive Materials

View full text Add to dashboard Cite

“…hPSCs can differentiate into all cell types found in the heart, making them an invaluable resource for developing hCOs [ 8 , 9 ]. Nonetheless, the techniques employed for generating hCOs from hPSCs vary significantly, resulting in differences in heart development, maturity, complexity, vascularization, and spatial structure [ 10 , 11 ].…”

Section: Introductionmentioning

confidence: 99%

A review of protocols for engineering human cardiac organoids

Wu,

He,

et al. 2023

Heliyon

View full text Add to dashboard Cite

Experimental Tools as an “Alternative to Animal Research” in Pharmacology

Sulakhiya,

Paliwal,

Kisku

et al. 2024

Software and Programming Tools in Pharmaceutical Research

View full text Add to dashboard Cite

Experimental tools have emerged as a promising alternative to animal research in pharmacology. With growing ethical concerns and regulatory restrictions surrounding animal experimentation, researchers are increasingly turning towards in vitro and in silico methods to develop new drugs and evaluate their safety and efficacy. In vitro tools include cell culture systems, 3D organoid models, and microfluidic devices replicating complex physiological conditions, such as the blood-brain barrier or the liver microenvironment. These systems can provide more accurate and predictive results than animal models, reducing ethical concerns and experimental costs. In silico methods, such as computer modelling, simulation, and artificial intelligence, enable researchers to predict the drug-target interactions, toxicity, and pharmacokinetic and pharmacodynamic properties of new drugs without animal testing. Experimental tools have several advantages over animal research, including more accurate and predictive results, lower costs, higher throughput, and reduced ethical concerns. However, the limitations of these tools must also be acknowledged, such as the inability to fully replicate the complexity of a living organism, which requires further validation. These tools offer a promising avenue for advancing pharmacological research while reducing the reliance on animal experimentation. In conclusion, experimental tools provide an excellent alternative to animal research in pharmacology to identify and avoid potential toxicities early in the drug discovery process and have the potential to revolutionize drug discovery and development. This chapter mainly focuses on the numerous in vitro, in silico, non-animal in vivo, and emerging experimental tools and their regulatory perspectives on validation, acceptance, and implementation of the alternative methods used in pharmacological research.

show abstract

Promises and challenges of cardiac organoids

Cited by 3 publications

References 43 publications

Progress of organoid platform in cardiovascular research

Progress of organoid platform in cardiovascular research

A review of protocols for engineering human cardiac organoids

Experimental Tools as an “Alternative to Animal Research” in Pharmacology

Contact Info

Product

Resources

About